Home/Pipeline/LUPKYNIS (voclosporin)

LUPKYNIS (voclosporin)

Lupus Nephritis

Approved/CommercialMarketedNCT03021499, NCT03597464

Key Facts

Indication

Lupus Nephritis

Phase

Approved/Commercial

Status

Marketed

Company

Aurinia Pharmaceuticals

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to delivering new treatment options to patients with autoimmune diseases. Its primary achievement is the FDA approval and commercialization of LUPKYNIS (voclosporin), a novel calcineurin inhibitor for lupus nephritis, a serious kidney manifestation of systemic lupus erythematosus. The company is strategically focused on maximizing the commercial potential of LUPKYNIS while exploring its application in other autoimmune indications. Aurinia's mission centers on addressing significant unmet medical needs in nephrology and rheumatology.

View full company profile

Therapeutic Areas

Autoimmune Diseases Nephrology Rheumatology

Other Lupus Nephritis Drugs

Drug	Company	Phase	Status
Atacicept	Vera Therapeutics	Phase 2	Active (TRAIN trial)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio	Phase 1/2	Active, Recruiting
Zetomipzomib	Kezar Life Sciences	Phase 2	Active